UBS Group’s Aratana Therapeutics, Inc. PETX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-7,176
| Closed | -$37K | – | 8581 |
|
|
2019
Q2 | $37K | Sell |
7,176
-5,375
| -43% | -$24.2K | ﹤0.01% | 6178 |
|
|
2019
Q1 | $46K | Sell |
12,551
-6,663
| -35% | -$28.9K | ﹤0.01% | 5623 |
|
|
2018
Q4 | $118K | Buy |
19,214
+7,863
| +69% | +$48K | ﹤0.01% | 5403 |
|
|
2018
Q3 | $66K | Sell |
11,351
-661
| -6% | -$3.3K | ﹤0.01% | 5952 |
|
|
2018
Q2 | $51K | Buy |
12,012
+2,961
| +33% | +$14.9K | ﹤0.01% | 5949 |
|
|
2018
Q1 | $40K | Sell |
9,051
-3,758
| -29% | -$16.8K | ﹤0.01% | 5889 |
|
|
2017
Q4 | $68K | Buy |
12,809
+3
| +0% | +$18 | ﹤0.01% | 5613 |
|
|
2017
Q3 | $79K | Buy |
12,806
+1,343
| +12% | +$8.5K | ﹤0.01% | 5483 |
|
|
2017
Q2 | $83K | Buy |
11,463
+1,102
| +11% | +$6.78K | ﹤0.01% | 5294 |
|
|
2017
Q1 | $55K | Buy |
10,361
+3,147
| +44% | +$21.2K | ﹤0.01% | 5454 |
|
|
2016
Q4 | $52K | Sell |
7,214
-1,267
| -15% | -$10.2K | ﹤0.01% | 5805 |
|
|
2016
Q3 | $79K | Buy |
8,481
+4,476
| +112% | +$37.2K | ﹤0.01% | 5146 |
|
|
2016
Q2 | $26K | Buy |
4,005
+573
| +17% | +$3.69K | ﹤0.01% | 6087 |
|
|
2016
Q1 | $19K | Buy |
3,432
+3,081
| +878% | +$11.6K | ﹤0.01% | 6262 |
|
|
2015
Q4 | $2K | Sell |
351
-349
| -50% | -$2.31K | ﹤0.01% | 8066 |
|
|
2015
Q3 | $6K | Hold |
700
| – | – | ﹤0.01% | 7638 |
|
|
2015
Q2 | $11K | Sell |
700
-2,577
| -79% | -$37.2K | ﹤0.01% | 7414 |
|
|
2015
Q1 | $52K | Buy |
3,277
+727
| +29% | +$12.9K | ﹤0.01% | 6014 |
|
|
2014
Q4 | $45K | Buy |
+2,550
| New | +$31.8K | ﹤0.01% | 6630 |
|
Other funds holding PETX
UBS Group's PETX Position: Q3 2019 in Review
UBS Group sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 7,176 shares — an estimated $37K sold.
UBS Group first reported a position in PETX in Q4 2014 and held it in 19 quarters. The position peaked at $118K in Q4 2018. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.
- UBS Group reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
- UBS Group sold 7,176 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $37K.
- UBS Group first reported a position in Aratana Therapeutics, Inc. in Q4 2014 and held it in 19 quarters.
- UBS Group's Aratana Therapeutics, Inc. position peaked at $118K in Q4 2018.
- 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.
Based on UBS Group's 13F filing for Q3 2019, filed 14 Nov 2019.